Patents by Inventor John C. Emmett

John C. Emmett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridazinone derivatives
    Patent number: 4962110
    Abstract: The invention relates to 2-aminopyrimidinone derivatives that have utility as cardiac stimulants. A compound of the invention is 6-[4-(1,4-dihydro-4-oxo-2-pyrimidinylamino)phenyl]-5-methyl-4,5-dihydro-3( 2H)-pyridazinone.
    Type: Grant
    Filed: August 10, 1989
    Date of Patent: October 9, 1990
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: John C. Emmett, William J. Coates
  • Novel guanidino pyridazinones as cardiac stimulants
    Patent number: 4946842
    Abstract: The invention relates to phenyl dihydropyridazinone derivatives that have utility as cardiac stimulants. A compound of the invention is 6-[4-(N.sup.3 -benzyl-N.sup.2 -cyanoguanidino)phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone.
    Type: Grant
    Filed: June 30, 1986
    Date of Patent: August 7, 1990
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: William J. Coates, John C. Emmett, Robert A. Slater
  • Pyridyl and pyridazinyl substituted thyronine compounds
    Patent number: 4910305
    Abstract: This invention relates to chemical compounds which have selective thyromimetic activity. A compound of this invention is 3,5-dibromo-3'-[6-oxo-3(1H)-pyridazinylmethyl]-thyronine.
    Type: Grant
    Filed: March 16, 1988
    Date of Patent: March 20, 1990
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: David Ellis, John C. Emmett, Anthony H. Underwood, Paul D. Leeson
  • Chemical compounds having selective thyromimetic activity
    Patent number: 4826876
    Abstract: This invention relates to chemical compounds which have selective thyromimetic activity. A compound of this invention is 3,5-dibromo-3'-[6-oxo-3(1H)-pyridazinyl-methyl]-thyronine.
    Type: Grant
    Filed: December 21, 1987
    Date of Patent: May 2, 1989
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: David Ellis, John C. Emmett, Anthony H. Underwood, Paul D. Leeson
  • Pyridyl and pyridazinyl substituted thyronine compounds having selective thyromimetic activity
    Patent number: 4766121
    Abstract: This invention relates to chemical compounds which have selective thyromimetic activity. A compound of this invention is 3,5-dibromo-3'-[6-oxo-3(1H)-pyridazinylmethyl]-thyronine.
    Type: Grant
    Filed: January 14, 1986
    Date of Patent: August 23, 1988
    Assignee: Smith Kline & French Laboratories Ltd.
    Inventors: David Ellis, John C. Emmett, Anthony H. Underwood, Paul D. Leeson
  • Heterocyclic compounds having inotropic activity
    Patent number: 4657906
    Abstract: This invention relates to 5-(phenyl)-2(1H)-pyrazinones substituted in the 4-position of the phenyl ring by an amino or acylamino group. These compounds has inotropic activity. One specific compound is 5-(4-acetamidophenyl)-2(1H)-pyrazinone.
    Type: Grant
    Filed: September 19, 1985
    Date of Patent: April 14, 1987
    Assignee: Smith Kline & French Laboratories Ltd.
    Inventors: John C. Emmett, Robert A. Slater, Brian H. Warrington
  • 5-(4-substituted)phenyl-2-pyrazinones
    Patent number: 4632924
    Abstract: This invention relates to 5-(4-substituted)phenylpyrazinone compounds which have positive inotropic and vasodilator activity. One such compound is 5-(4-carboxamidophenyl)pyrazin-2(1H)-one.
    Type: Grant
    Filed: November 30, 1984
    Date of Patent: December 30, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: John C. Emmett, Robert A. Slater
  • Pharmacologically active compounds
    Patent number: 4600720
    Abstract: Heterocyclic compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors. A specific compound of this invention is 2-[2-(4-methyl-5-imidazolymethylthio)ethylamino]-4-pyrimidone.
    Type: Grant
    Filed: June 5, 1985
    Date of Patent: July 15, 1986
    Assignee: Smith Kline & French Laboratories Ltd.
    Inventors: Graham J. Durant, John C. Emmett, Charon R. Ganellin
  • Heterocyclic alkylaminoheterocycles
    Patent number: 4578459
    Abstract: Heterocyclic compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors. A specific compound of this invention is 2-[2-(4-methyl-5-imidazolylmethylthio)ethylamino]-4-pyrimidone.
    Type: Grant
    Filed: June 8, 1984
    Date of Patent: March 25, 1986
    Assignee: SmithKline & French Laboratories Limited
    Inventors: Graham J. Durant, John C. Emmett, Charon R. Ganellin
  • 5-(4-Amino or acylaminophenyl)-2(1H)-pyrazinones having inotropic activity
    Patent number: 4556711
    Abstract: This invention relates to 5-(phenyl)-2(1H)-pyrazinones substituted in the 4-position of the phenyl ring by an amino or acylamino group. These compounds have inotropic activity. One specific compound is 5-(4-acetamidophenyl)-2(1H)-pyrazinone.
    Type: Grant
    Filed: June 2, 1983
    Date of Patent: December 3, 1985
    Assignee: Smith Kline & French Laboratories Ltd.
    Inventors: John C. Emmett, Robert A. Slater, Brian H. Warrington
  • Pharmacologically active compounds
    Patent number: 4537779
    Abstract: Heterocyclic compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors. A specific compound of this invention is 2-[2-(4-methyl-5-imidazolylmethylthio)ethylamino]-4-pyrimidone.
    Type: Grant
    Filed: June 18, 1984
    Date of Patent: August 27, 1985
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: Graham J. Durant, John C. Emmett, Charon R. Ganellin
  • Pharmacologically active compounds
    Patent number: 4470985
    Abstract: Heterocyclic compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors. A specific compound of this invention is 2-[2-(4-methyl-5-imidazolylmethylthio)ethylamino]-4-pyrimidone.
    Type: Grant
    Filed: April 15, 1983
    Date of Patent: September 11, 1984
    Assignee: SmithKline & French Laboratories Limited
    Inventors: Graham J. Durant, John C. Emmett, Charon R. Ganellin
  • 1,2,4-Triazines
    Patent number: 4467087
    Abstract: Heterocyclic alkyl(or methylthioalkyl)amino-1,2,4-triazine compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors.
    Type: Grant
    Filed: September 24, 1982
    Date of Patent: August 21, 1984
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: Graham J. Durant, John C. Emmett, Charon R. Ganellin
  • Pharmacologically active compounds
    Patent number: 4399142
    Abstract: Heterocyclic compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors. A specific compound of this invention is 2-[2-(4-methyl-5-imidazolymethylthio)ethylamino]-4-pyrimidone.
    Type: Grant
    Filed: March 31, 1982
    Date of Patent: August 16, 1983
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: Graham J. Durant, John C. Emmett, Charon R. Ganellin
  • Imidazoline containing imidazoles
    Patent number: 4374251
    Abstract: Heterocyclic compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors. A specific compound of this invention is 2-[2-(4-methyl-5-imidazolylmethylthio)ethylamio]-4-pyrimidone.
    Type: Grant
    Filed: November 14, 1980
    Date of Patent: February 15, 1983
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: Graham J. Durant, John C. Emmett, Charon R. Ganellin
  • Pharmacologically active compounds
    Patent number: 4341787
    Abstract: Heterocyclic compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors. A specific compound of this invention is 2-[2-(4-methyl-5-imidazolylmethylthio)ethylamino]-4-pyrimidone.
    Type: Grant
    Filed: March 3, 1981
    Date of Patent: July 27, 1982
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: Graham J. Durant, John C. Emmett, Charon R. Ganellin
  • Triazole-substituted ethylene derivatives
    Patent number: 4317829
    Abstract: The compounds are ethylene derivatives which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors. A compound of this invention is 1-nitro-2-methylamino-2-[2-((4-methyl-5-imidazolyl)methylthio)ethylamino]e thylene.
    Type: Grant
    Filed: February 4, 1980
    Date of Patent: March 2, 1982
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: Graham J. Durant, John C. Emmett, Charon R. Ganellin, Hunter D. Prain
  • Inhibitors of H-2 histamine receptors
    Patent number: 4307101
    Abstract: The compounds are substituted thioalkyl-, aminoalkyl- and oxyalkyl-thioureas and ureas which are inhibitors of histamine activity.
    Type: Grant
    Filed: March 17, 1980
    Date of Patent: December 22, 1981
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: Graham J. Durant, John C. Emmett, Charon R. Ganellin
  • Pharmacologically active thiourea and urea compounds
    Patent number: 4293697
    Abstract: The compounds are substituted thioalkyl-, aminoalkyl- and oxyalkyl-thioureas and ureas which are inhibitors of histamine activity.
    Type: Grant
    Filed: April 9, 1980
    Date of Patent: October 6, 1981
    Assignee: Smith, Kline & French Laboratories Limited
    Inventors: Graham J. Durant, John C. Emmett, Charon R. Ganellin
  • Pharmacologically active guanidine compounds
    Patent number: 4293699
    Abstract: The compounds are substituted thioalkyl-, aminoalkyl- and oxyalkyl-guanidines which are inhibitors of histamine activity.
    Type: Grant
    Filed: March 21, 1980
    Date of Patent: October 6, 1981
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: Graham J. Durant, John C. Emmett, Charon R. Ganellin